Login / Register

Oxford Peptide Labs-Logo
SHIPPED STRAIGHT FROM OUR FREEZER
24 MONTH SHELF LIFE
HPLC TESTED 99%+ PURITY
SHIPPED WITHIN 24 HOURS
Retatrutide 30mg - Oxford Peptide Labs
International Orders
VIAL0001
Test HPLC
OVER 80K+
Retatrutide 30mg - Oxford Peptide Labs
International Orders
VIAL0001
Test HPLC
OVER 80K+

Retatrutide

Price range: £60.00 through £150.00

In stock
High-purity Retatrutide (LY3437943) lyophilized powder, a triple-agonist targeting GLP-1, GIP, and Glucagon receptors for advanced metabolic and obesity research.

Description

Retatrutide (LY3437943) is a novel synthetic peptide that functions as a triple hormone receptor agonist, simultaneously targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This unique “tri-agonist” mechanism facilitates a synergistic approach to metabolic regulation, promoting significant weight loss, improved glycemic control, and enhanced lipid metabolism. Research indicates it may offer superior efficacy compared to mono- or dual-agonists by increasing energy expenditure while suppressing appetite.

Additional information

Vial Size

,

Reviews

There are no reviews yet.

Be the first to review “Retatrutide”

Your email address will not be published. Required fields are marked *

No more offers for this product!

General Inquiries

There are no inquiries yet.

SKU N/A Category Tags , , Brand:
  • Download COA here:
Download COA (PDF)

Please note if you have a different Batch ID please contact us for the latest COA.

Chemical Specifications:

  • Chemical Name: Retatrutide

  • Synonyms: LY3437943, GIP/GLP-1/Glucagon Triple Agonist

  • CAS Number: 2381089-83-2

  • Molecular Formula: C${221}$H${342}$N${46}$O${68}$

  • Molecular Weight: 4731.33 g/mol (Peptide)

  • Sequence: Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Leu-Leu-Asp-Lys-Lys-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

  • Structure: Linear peptide modified with a C20 fatty acid diacid moiety.

Description & Mechanism
Retatrutide (LY3437943) is a novel synthetic peptide that functions as a triple hormone receptor agonist, simultaneously targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This unique “tri-agonist” mechanism facilitates a synergistic approach to metabolic regulation, promoting significant weight loss, improved glycemic control, and enhanced lipid metabolism. Research indicates it may offer superior efficacy compared to mono- or dual-agonists by increasing energy expenditure while suppressing appetite.

  • Obesity Research: Investigated for its potential to induce substantial weight reduction by combining appetite suppression (GLP-1/GIP) with increased energy expenditure (Glucagon).

  • Glycemic Control: Studies suggest it improves insulin sensitivity and glucose homeostasis in models of Type 2 Diabetes.

  • Hepatic Health: Research indicates potential benefits in significantly reducing liver fat content, relevant for metabolic dysfunction-associated steatotic liver disease (MASLD).

  • Lipid Metabolism: Observed to improve lipid profiles in research subjects, including reductions in triglycerides and LDL cholesterol.

  • Formulation: Lyophilized powder.

  • Storage: -20°C for powder, -80°C for reconstituted solution.

  • Reconstitution: Bacteriostatic water or sterile saline.

  • Purity: ≥99% (HPLC)

  • Grade: Research Grade

  • Appearance: White lyophilized powder

  • Solubility: Soluble in water, PBS, or sterile saline.

For Research Use Only. Not for human consumption.

  • Adverse Events: In clinical research, common adverse events included gastrointestinal symptoms such as nausea, diarrhea, vomiting, and constipation.

  • Cardiac Monitoring: Studies have noted dose-dependent transient increases in heart rate; monitoring is standard in research protocols.

  • Investigational Status: This compound is currently under investigation in Phase 3 clinical trials and is not approved for therapeutic use.

  1. Jastreboff, A. M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514-526.

  2. Rosenstock, J., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet, 402(10401), 529-544.

  3. Coskun, T., et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet, 400(10366), 1869-1881.

In stock

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies are performed outside of the body. These products are not medicines or drugs and have not been approved to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden.